<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33785835</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2045-2322</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>30</Day>
            </PubDate>
          </JournalIssue>
          <Title>Scientific reports</Title>
          <ISOAbbreviation>Sci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>In oxygen-deprived tumor cells ERp57 provides radioprotection and ensures proliferation via c-Myc, PLK1 and the AKT pathway.</ArticleTitle>
        <Pagination>
          <StartPage>7199</StartPage>
          <MedlinePgn>7199</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">7199</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-86658-5</ELocationID>
        <Abstract>
          <AbstractText>The disulfide isomerase ERp57, originally found in the endoplasmic reticulum, is located in multiple cellular compartments, participates in diverse cell functions and interacts with a huge network of binding partners. It was recently suggested as an attractive new target for cancer therapy due to its critical role in tumor cell proliferation. Since a major bottleneck in cancer treatment is the occurrence of hypoxic areas in solid tumors, the role of ERp57 in cell growth was tested under oxygen depletion in the colorectal cancer cell line HCT116. We observed a severe growth inhibition when ERp57 was knocked down in hypoxia (1% O<sub>2</sub>) as a consequence of downregulated c-Myc, PLK1, PDPK1 (PDK1) and AKT (PKB). Further, irradiation experiments revealed also a radiosensitizing effect of ERp57 depletion under oxygen deprivation. Compared to ERp57, we do not favour PDPK1 as a suitable pharmaceutical target as its efficient knockdown/chemical inhibition did not show an inhibitory effect on proliferation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ocklenburg</LastName>
            <ForeName>Tobias</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Neumann</LastName>
            <ForeName>Fabian</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolf</LastName>
            <ForeName>Alexandra</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vogel</LastName>
            <ForeName>Julia</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Göpelt</LastName>
            <ForeName>Kirsten</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baumann</LastName>
            <ForeName>Melanie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Baumann</LastName>
            <ForeName>Jennifer</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kranz</LastName>
            <ForeName>Philip</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Metzen</LastName>
            <ForeName>Eric</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Institut Für Physiologie, Universität Duisburg-Essen, Duisburg, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Brockmeier</LastName>
            <ForeName>Ulf</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University Hospital Essen, Essen, Germany. ulf.brockmeier@uni-due.de.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>03</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Sci Rep</MedlineTA>
        <NlmUniqueID>101563288</NlmUniqueID>
        <ISSNLinking>2045-2322</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C489427">MYC protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C090134">polo-like kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.3.4.1</RegistryNumber>
          <NameOfSubstance UI="D019704">Protein Disulfide-Isomerases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 5.3.4.1.</RegistryNumber>
          <NameOfSubstance UI="C085868">PDIA3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003110" MajorTopicYN="N">Colonic Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045325" MajorTopicYN="N">HCT116 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019704" MajorTopicYN="N">Protein Disulfide-Isomerases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016271" MajorTopicYN="N">Proto-Oncogene Proteins c-myc</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000072258" MajorTopicYN="Y">Tumor Hypoxia</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33785835</ArticleId>
        <ArticleId IdType="pmc">PMC8009878</ArticleId>
        <ArticleId IdType="doi">10.1038/s41598-021-86658-5</ArticleId>
        <ArticleId IdType="pii">10.1038/s41598-021-86658-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>De Rosa M, et al.  Genetics, diagnosis and management of colorectal cancer (review) Oncol. Rep. 2015;34:1087–1096. doi: 10.3892/or.2015.4108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2015.4108</ArticleId>
            <ArticleId IdType="pmc">PMC4530899</ArticleId>
            <ArticleId IdType="pubmed">26151224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pandurangan AK, et al.  Colorectal carcinogenesis: insights into the cell death and signal transduction pathways: a review. World J. Gastrointest. Oncol. 2018;10:244–259. doi: 10.4251/wjgo.v10.i9.244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4251/wjgo.v10.i9.244</ArticleId>
            <ArticleId IdType="pmc">PMC6147765</ArticleId>
            <ArticleId IdType="pubmed">30254720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int. J. Nanomed. 2018;13:6049–6058. doi: 10.2147/IJN.S140462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJN.S140462</ArticleId>
            <ArticleId IdType="pmc">PMC6177375</ArticleId>
            <ArticleId IdType="pubmed">30323592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol. Ther. 2016;164:152–169. doi: 10.1016/j.pharmthera.2016.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2016.04.009</ArticleId>
            <ArticleId IdType="pubmed">27139518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F, et al.  Radiation induces the generation of cancer stem cells: a novel mechanism for cancer radioresistance. Oncol. Lett. 2016;12:3059–3065. doi: 10.3892/ol.2016.5124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2016.5124</ArticleId>
            <ArticleId IdType="pmc">PMC5103903</ArticleId>
            <ArticleId IdType="pubmed">27899964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettersen EO, et al.  Targeting tumour hypoxia to prevent cancer metastasis: from biology, biosensing and technology to drug development. J. Enzyme Inhib. Med. Chem. 2015;30:689–721. doi: 10.3109/14756366.2014.966704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/14756366.2014.966704</ArticleId>
            <ArticleId IdType="pubmed">25347767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al.  ERp57 does not require interactions with calnexin and calreticulin to promote assembly of class I histocompatibility molecules, and it enhances peptide loading independently of its redox activity. J. Biol. Chem. 2009;284:10160–10173. doi: 10.1074/jbc.M808356200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M808356200</ArticleId>
            <ArticleId IdType="pmc">PMC2665070</ArticleId>
            <ArticleId IdType="pubmed">19196713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kozlov, G. et al. Crystal structure of the bb' domains of the protein disulfide isomerase ERp57. Structure (London, England : 1993)14, 1331–1339 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16905107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussmann, M. et al. Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits proliferation and increases sensitivity to ionizing radiation and chemotherapeutics. Oncotarget6, 39247–39261. 10.18632/oncotarget.5746 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4770770</ArticleId>
            <ArticleId IdType="pubmed">26513173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007;8:519–529. doi: 10.1038/nrm2199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm2199</ArticleId>
            <ArticleId IdType="pubmed">17565364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kranz P, et al.  PDI is an essential redox-sensitive activator of PERK during the unfolded protein response (UPR) Cell Death Dis. 2017;8:e2986. doi: 10.1038/cddis.2017.369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2017.369</ArticleId>
            <ArticleId IdType="pmc">PMC5596557</ArticleId>
            <ArticleId IdType="pubmed">28796255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramirez-Rangel I, et al.  Regulation of mTORC1 complex assembly and signaling by GRp58/ERp57. Mol. Cell. Biol. 2011;31:1657–1671. doi: 10.1128/MCB.00824-10;10.1128/MCB.00824-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.00824-10;10.1128/MCB.00824-10</ArticleId>
            <ArticleId IdType="pmc">PMC3126338</ArticleId>
            <ArticleId IdType="pubmed">21321085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo, G. G. et al. Association of the chaperone glucose-regulated protein 58 (GRP58/ER-60/ERp57) with Stat3 in cytosol and plasma membrane complexes. J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res.22, 555–563. 10.1089/10799900252982034 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12060494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene. 2007;26:2027–2038. doi: 10.1038/sj.onc.1210008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1210008</ArticleId>
            <ArticleId IdType="pubmed">17043658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinoshita M, Johnson DL, Shatney CH, Lee YL, Mochizuki H. Cancer cells surviving hypoxia obtain hypoxia resistance and maintain anti-apoptotic potential under reoxygenation. Int. J. Cancer. 2001;91:322–326. doi: 10.1002/1097-0215(200002)9999:9999&lt;::aid-ijc1064&gt;3.0.co;2-p.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1097-0215(200002)9999:9999&lt;::aid-ijc1064&gt;3.0.co;2-p</ArticleId>
            <ArticleId IdType="pubmed">11169954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274. doi: 10.1016/j.cell.2007.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.06.009</ArticleId>
            <ArticleId IdType="pmc">PMC2756685</ArticleId>
            <ArticleId IdType="pubmed">17604717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Z, Sun Q, Wang X. PLK1, A potential target for cancer therapy. Transl. Oncol. 2017;10:22–32. doi: 10.1016/j.tranon.2016.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tranon.2016.10.003</ArticleId>
            <ArticleId IdType="pmc">PMC5124362</ArticleId>
            <ArticleId IdType="pubmed">27888710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and cancer. Cancer Discov. 2015;5:1024–1039. doi: 10.1158/2159-8290.CD-15-0507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-0507</ArticleId>
            <ArticleId IdType="pmc">PMC4592441</ArticleId>
            <ArticleId IdType="pubmed">26382145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grillo C, et al.  Cooperative activity of Ref-1/APE and ERp57 in reductive activation of transcription factors. Free Radic. Biol. Med. 2006;41:1113–1123. doi: 10.1016/j.freeradbiomed.2006.06.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.freeradbiomed.2006.06.016</ArticleId>
            <ArticleId IdType="pubmed">16962936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chichiarelli S, et al.  The stress protein ERp57/GRP58 binds specific DNA sequences in HeLa cells. J. Cell. Physiol. 2007;210:343–351. doi: 10.1002/jcp.20824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.20824</ArticleId>
            <ArticleId IdType="pubmed">17061245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aureli C, et al.  ERp57/PDIA3 binds specific DNA fragments in a melanoma cell line. Gene. 2013;524:390–395. doi: 10.1016/j.gene.2013.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2013.04.004</ArticleId>
            <ArticleId IdType="pubmed">23587917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayascas JR. PDK1: the major transducer of PI 3-kinase actions. Curr. Top. Microbiol. Immunol. 2010;346:9–29. doi: 10.1007/82_2010_43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/82_2010_43</ArticleId>
            <ArticleId IdType="pubmed">20563709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan J, et al.  PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 2013;3:1156–1171. doi: 10.1158/2159-8290.cd-12-0595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.cd-12-0595</ArticleId>
            <ArticleId IdType="pubmed">23887393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellwood-Yen K, et al.  PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res. 2011;71:3052–3065. doi: 10.1158/0008-5472.can-10-2282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-10-2282</ArticleId>
            <ArticleId IdType="pubmed">21493594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gocher AM, et al.  Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J. Biol. Chem. 2017;292:14188–14204. doi: 10.1074/jbc.M117.778464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M117.778464</ArticleId>
            <ArticleId IdType="pmc">PMC5572912</ArticleId>
            <ArticleId IdType="pubmed">28634229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anti-cancer treatments. Pharmacol. Ther. 2017;172:101–115. doi: 10.1016/j.pharmthera.2016.12.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2016.12.001</ArticleId>
            <ArticleId IdType="pmc">PMC6143165</ArticleId>
            <ArticleId IdType="pubmed">27919797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nussinov R, Jang H, Tsai CJ. The structural basis for cancer treatment decisions. Oncotarget. 2014;5:7285–7302. doi: 10.18632/oncotarget.2439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2439</ArticleId>
            <ArticleId IdType="pmc">PMC4202123</ArticleId>
            <ArticleId IdType="pubmed">25277176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rutkevich LA, Cohen-Doyle MF, Brockmeier U, Williams DB. Functional relationship between protein disulfide isomerase family members during the oxidative folding of human secretory proteins. Mol. Biol. Cell. 2010;21:3093–3105. doi: 10.1091/mbc.e10-04-0356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.e10-04-0356</ArticleId>
            <ArticleId IdType="pmc">PMC2938376</ArticleId>
            <ArticleId IdType="pubmed">20660153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hettinghouse A, Liu R, Liu CJ. Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol. Ther. 2018;181:34–48. doi: 10.1016/j.pharmthera.2017.07.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2017.07.011</ArticleId>
            <ArticleId IdType="pmc">PMC5743601</ArticleId>
            <ArticleId IdType="pubmed">28723413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chichiarelli S, et al.  The stress protein ERp57/GRP58 binds specific DNA sequences in HeLa cells. J. Cell Physiol. 2007;210:343–351. doi: 10.1002/jcp.20824.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.20824</ArticleId>
            <ArticleId IdType="pubmed">17061245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY. Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol. Cancer Ther. 2009;8:864–872. doi: 10.1158/1535-7163.MCT-08-0695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-08-0695</ArticleId>
            <ArticleId IdType="pmc">PMC2684979</ArticleId>
            <ArticleId IdType="pubmed">19372559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samanta S, et al.  Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget. 2017;8:103543–103556. doi: 10.18632/oncotarget.21569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.21569</ArticleId>
            <ArticleId IdType="pmc">PMC5732749</ArticleId>
            <ArticleId IdType="pubmed">29262583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vacante, M., Borzì, A. M., Basile, F. &amp; Biondi, A. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J. Clin. Cases6, 869–881. 10.12998/wjcc.v6.i15.869 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6288499</ArticleId>
            <ArticleId IdType="pubmed">30568941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coe H, Jung J, Groenendyk J, Prins D, Michalak M. ERp57 modulates STAT3 signaling from the lumen of the endoplasmic reticulum. J. Biol. Chem. 2010;285:6725–6738. doi: 10.1074/jbc.M109.054015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.054015</ArticleId>
            <ArticleId IdType="pmc">PMC2825467</ArticleId>
            <ArticleId IdType="pubmed">20022947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leys CM, et al.  Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 2007;141:41–50. doi: 10.1016/j.surg.2006.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2006.05.009</ArticleId>
            <ArticleId IdType="pubmed">17188166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao CJ, et al.  Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer. Cancer Sci. 2011;102:2255–2263. doi: 10.1111/j.1349-7006.2011.02102.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2011.02102.x</ArticleId>
            <ArticleId IdType="pubmed">21917082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chichiarelli S, et al.  Role of ERp57 in the signaling and transcriptional activity of STAT3 in a melanoma cell line. Arch. Biochem. Biophys. 2010;494:178–183. doi: 10.1016/j.abb.2009.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.abb.2009.12.004</ArticleId>
            <ArticleId IdType="pubmed">19995546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cicchillitti L, et al.  Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin. Int. J. Oncol. 2010;37:445–454. doi: 10.3892/ijo_00000693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo_00000693</ArticleId>
            <ArticleId IdType="pubmed">20596672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cole KS, et al.  Characterization of an A-site selective protein disulfide isomerase A1 inhibitor. Biochemistry. 2018;57:2035–2043. doi: 10.1021/acs.biochem.8b00178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.biochem.8b00178</ArticleId>
            <ArticleId IdType="pmc">PMC5884060</ArticleId>
            <ArticleId IdType="pubmed">29521097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kyani A, et al.  Discovery and mechanistic elucidation of a class of protein disulfide isomerase inhibitors for the treatment of glioblastoma. ChemMedChem. 2018;13:164–177. doi: 10.1002/cmdc.201700629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cmdc.201700629</ArticleId>
            <ArticleId IdType="pmc">PMC6242712</ArticleId>
            <ArticleId IdType="pubmed">29235250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Won JK, et al.  Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology. 2017;66:855–868. doi: 10.1002/hep.29237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.29237</ArticleId>
            <ArticleId IdType="pubmed">28439950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vatolin S, et al.  Novel protein disulfide isomerase inhibitor with anticancer activity in multiple myeloma. Cancer Res. 2016;76:3340–3350. doi: 10.1158/0008-5472.can-15-3099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.can-15-3099</ArticleId>
            <ArticleId IdType="pubmed">27197150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu S, et al.  Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc. Natl. Acad. Sci. USA. 2012;109:16348–16353. doi: 10.1073/pnas.1205226109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1205226109</ArticleId>
            <ArticleId IdType="pmc">PMC3479552</ArticleId>
            <ArticleId IdType="pubmed">22988091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Naismith JH. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnol. 2008;8:91. doi: 10.1186/1472-6750-8-91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1472-6750-8-91</ArticleId>
            <ArticleId IdType="pmc">PMC2629768</ArticleId>
            <ArticleId IdType="pubmed">19055817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janke K, et al.  Factor inhibiting HIF-1 (FIH-1) modulates protein interactions of apoptosis-stimulating p53 binding protein 2 (ASPP2) J. Cell Sci. 2013;126:2629–2640. doi: 10.1242/jcs.117564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.117564</ArticleId>
            <ArticleId IdType="pubmed">23606740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat. Protocols. 2006;1:2315–2319. doi: 10.1038/nprot.2006.339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2006.339</ArticleId>
            <ArticleId IdType="pubmed">17406473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kvietikova I, Wenger RH, Marti HH, Gassmann M. The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res. 1995;23:4542–4550. doi: 10.1093/nar/23.22.4542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/23.22.4542</ArticleId>
            <ArticleId IdType="pmc">PMC307423</ArticleId>
            <ArticleId IdType="pubmed">8524640</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
